Knight Therapeutics Inc. Announces Regulatory Submission of CREXONT® for Parkinson's Disease Treatment in Mexico

Reuters

08/05

<a href="https://laohu8.com/S/KHTRF">Knight Therapeutics Inc</a>. Announces Regulatory Submission of CREXONT® for Parkinson's Disease Treatment in Mexico

Knight Therapeutics Inc. has announced that its Mexican affiliate, Grupo Biotoscana de Especialidad S.A. de C.V., has submitted a marketing authorization application for CREXONT® to COFEPRIS, the Mexican health regulatory agency. This submission marks a significant step in Knight's effort to expand its neurology portfolio and address the high unmet medical needs in the treatment of Parkinson's disease. CREXONT® is a novel, extended-release oral formulation of carbidopa/levodopa, intended for the treatment of Parkinson's disease and other related conditions. The application in Mexico follows a similar submission in Canada, where Health Canada has accepted CREXONT® for review. Knight Therapeutics holds the exclusive rights to seek regulatory approval and commercialize CREXONT® in Canada and Latin America through an agreement with Amneal Pharmaceuticals, Inc.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Knight Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9506078-en) on August 05, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2557396187"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2557396187\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2557396187?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-05 19:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2557396187","market":"fut","top_or_hot":-1,"title":"Knight Therapeutics Inc. Announces Regulatory Submission of CREXONT® for Parkinson's Disease Treatment in Mexico","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/KHTRF\">Knight Therapeutics Inc</a>. Announces Regulatory Submission of CREXONT® for Parkinson's Disease Treatment in Mexico\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Knight <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc. has announced that its Mexican affiliate, Grupo Biotoscana de Especialidad S.A. de C.V., has submitted a marketing authorization application for CREXONT® to COFEPRIS, the Mexican health regulatory agency. This submission marks a significant step in Knight's effort to expand its neurology portfolio and address the high unmet medical needs in the treatment of Parkinson's disease. CREXONT® is a novel, extended-release oral formulation of carbidopa/levodopa, intended for the treatment of Parkinson's disease and other related conditions. The application in Mexico follows a similar submission in Canada, where Health Canada has accepted CREXONT® for review. Knight Therapeutics holds the exclusive rights to seek regulatory approval and commercialize CREXONT® in Canada and Latin America through an agreement with <a href=\"https://laohu8.com/S/AMRX\">Amneal Pharmaceuticals, Inc.</a>\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Knight Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9506078-en) on August 05, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Knight Therapeutics Inc. Announces Regulatory Submission of CREXONT® for Parkinson's Disease Treatment in Mexico</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKnight Therapeutics Inc. Announces Regulatory Submission of CREXONT® for Parkinson's Disease Treatment in Mexico\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-08-05 19:30</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/KHTRF\">Knight Therapeutics Inc</a>. Announces Regulatory Submission of CREXONT® for Parkinson's Disease Treatment in Mexico\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Knight <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc. has announced that its Mexican affiliate, Grupo Biotoscana de Especialidad S.A. de C.V., has submitted a marketing authorization application for CREXONT® to COFEPRIS, the Mexican health regulatory agency. This submission marks a significant step in Knight's effort to expand its neurology portfolio and address the high unmet medical needs in the treatment of Parkinson's disease. CREXONT® is a novel, extended-release oral formulation of carbidopa/levodopa, intended for the treatment of Parkinson's disease and other related conditions. The application in Mexico follows a similar submission in Canada, where Health Canada has accepted CREXONT® for review. Knight Therapeutics holds the exclusive rights to seek regulatory approval and commercialize CREXONT® in Canada and Latin America through an agreement with <a href=\"https://laohu8.com/S/AMRX\">Amneal Pharmaceuticals, Inc.</a>\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Knight Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9506078-en) on August 05, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0314104364.USD","symbol_name":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250805:nNDLbKc4Xl:1","article_id":"2557396187","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2557396187","pubTimestamp":1754393428,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Knight Therapeutics Inc. has announced that its Mexican affiliate, Grupo Biotoscana de Especialidad S.A. de C.V., has submitted a marketing authorization application for CREXONT to COFEPRIS, the Mexican health regulatory agency. This submission marks a significant step in Knight's effort to expand its neurology portfolio and address the high unmet medical needs in the treatment of Parkinson's disease. CREXONT is a novel, extended-release oral formulation of carbidopa/levodopa, intended for the treatment of Parkinson's disease and other related conditions. The application in Mexico follows a similar submission in Canada, where Health Canada has accepted CREXONT for review. Knight Therapeutics holds the exclusive rights to seek regulatory approval and commercialize CREXONT in Canada and Latin America through an agreement with Amneal Pharmaceuticals, Inc.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","AMRX":"Amneal Pharmaceuticals, Inc.","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","NDAQ":"纳斯达克OMX交易所","BK4007":"制药","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","BK4588":"碎股","BK4585":"ETF&股票定投概念","BK4112":"金融交易所和数据","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC"},"translate_title":"Knight Therapeutics Inc.宣布向监管机构提交CREXONT®用于墨西哥的帕金森病治疗","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AMRX":0.9,"NDAQ":0.9},"content_text":"Knight Therapeutics Inc. Announces Regulatory Submission of CREXONT® for Parkinson's Disease Treatment in Mexico\n    \n\n        Knight Therapeutics Inc. has announced that its Mexican affiliate, Grupo Biotoscana de Especialidad S.A. de C.V., has submitted a marketing authorization application for CREXONT® to COFEPRIS, the Mexican health regulatory agency. This submission marks a significant step in Knight's effort to expand its neurology portfolio and address the high unmet medical needs in the treatment of Parkinson's disease. CREXONT® is a novel, extended-release oral formulation of carbidopa/levodopa, intended for the treatment of Parkinson's disease and other related conditions. The application in Mexico follows a similar submission in Canada, where Health Canada has accepted CREXONT® for review. Knight Therapeutics holds the exclusive rights to seek regulatory approval and commercialize CREXONT® in Canada and Latin America through an agreement with Amneal Pharmaceuticals, Inc.\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Knight Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9506078-en) on August 05, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}